Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 10:20am CEST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
08/26 DAIICHI SANKYO : Receives Additional Dosage Regimen Approval in Japan for Long-a..
08/26 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
08/24 DAIICHI SANKYO : Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban
08/24 DAIICHI SANKYO : Ex-ranbaxy owners oppose award to daiichi
08/11 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
08/11 DAIICHI SANKYO : Patent Issued for Pharmaceutical Composition Containing Diamine..
08/01 DAIICHI SANKYO : Announces Status Relating to Acquisition of Own Shares
07/28 DAIICHI SANKYO : Patent Issued for Optical Resolution Methods for Bicyclic Compo..
07/28 DAIICHI SANKYO : Reports from Daiichi Sankyo Advance Knowledge in Ophthalmology ..
07/28 REPORT SUMMARIZES IMMUNOGLOBULINS ST : A novel afucosylated mAb directed at B7-H..
More news
Sector news : Pharmaceuticals - NEC
08/27 Stada shareholder AOC pushes through board reshuffle
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/18 FDA rejects Portola's AndexXa NDA; shares down 18% premarket
07/15 Therapy Focus - Another Try For FGFR Inhibitors
07/14 Amgen and Daiichi Sankyo team up to market biosimilars in Japan
06/01 Nektar Therapeutics inks deal with Daiichi Sankyo for European rights to Onze..
04/26 Aviragen sells portion of Inavir royalty rights for $20M
Advertisement
Financials ( JPY)
Sales 2017 913 800 M
EBIT 2017 104 000 M
Net income 2017 66 473 M
Finance 2017 199 117 M
Yield 2017 2,98%
P/E ratio 2017 23,33
P/E ratio 2018 23,99
EV / Sales 2017 1,61x
EV / Sales 2018 1,53x
Capitalization 1 667 949 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 502  JPY
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura Vice President-Finance & Accounting Department
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..-5.64%16 374
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
ASTRAZENECA PLC7.33%173 797
More Results